Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2014, and highlighted recent progress in advancing its pipeline.
“Alnylam made excellent progress in the fourth quarter of 2014 and the recent period, as we continued advancing RNAi therapeutics in clinical studies.
Help employers find you! Check out all the jobs and post your resume.
